|
|
|
|
| LEADER |
04466nma a2201249 u 4500 |
| 001 |
EB002043661 |
| 003 |
EBX01000000000000001187327 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
220822 ||| eng |
| 020 |
|
|
|a 9783036538358
|
| 020 |
|
|
|a 9783036538365
|
| 020 |
|
|
|a books978-3-0365-3836-5
|
| 100 |
1 |
|
|a Garcia-Medina, Jose Javier
|
| 245 |
0 |
0 |
|a Recent Clinical Research on Glaucoma
|h Elektronische Ressource
|
| 260 |
|
|
|a Basel
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2022
|
| 300 |
|
|
|a 1 electronic resource (236 p.)
|
| 653 |
|
|
|a structure
|
| 653 |
|
|
|a retinal glial cells
|
| 653 |
|
|
|a microglia
|
| 653 |
|
|
|a optical coherence tomography-angiography
|
| 653 |
|
|
|a retina
|
| 653 |
|
|
|a function
|
| 653 |
|
|
|a optic nerve
|
| 653 |
|
|
|a perimetry
|
| 653 |
|
|
|a subclinical keratoconus
|
| 653 |
|
|
|a vascular density
|
| 653 |
|
|
|a macula
|
| 653 |
|
|
|a genes
|
| 653 |
|
|
|a inflammation
|
| 653 |
|
|
|a VEGF
|
| 653 |
|
|
|a next generation sequencing
|
| 653 |
|
|
|a n/a
|
| 653 |
|
|
|a sport
|
| 653 |
|
|
|a macular segmentation
|
| 653 |
|
|
|a phenotype
|
| 653 |
|
|
|a acrobatic gymnastics
|
| 653 |
|
|
|a tears
|
| 653 |
|
|
|a deep learning
|
| 653 |
|
|
|a saffron
|
| 653 |
|
|
|a suture trabeculotomy ab interno
|
| 653 |
|
|
|a cytokines
|
| 653 |
|
|
|a Schlemm's canal incision
|
| 653 |
|
|
|a risk factor
|
| 653 |
|
|
|a glaucoma
|
| 653 |
|
|
|a peripapillary vessel density
|
| 653 |
|
|
|a miRNAs
|
| 653 |
|
|
|a aqueous outflow
|
| 653 |
|
|
|a ocular health
|
| 653 |
|
|
|a BDNF
|
| 653 |
|
|
|a vessel density
|
| 653 |
|
|
|a signaling pathways
|
| 653 |
|
|
|a peripapillary
|
| 653 |
|
|
|a neurodegeneration
|
| 653 |
|
|
|a glaucoma suspect
|
| 653 |
|
|
|a cornea biomechanics
|
| 653 |
|
|
|a apoptosis
|
| 653 |
|
|
|a correlation
|
| 653 |
|
|
|a physical exercise
|
| 653 |
|
|
|a Corvis® ST
|
| 653 |
|
|
|a biomarkers
|
| 653 |
|
|
|a OCT
|
| 653 |
|
|
|a inner
|
| 653 |
|
|
|a hand balance
|
| 653 |
|
|
|a disc
|
| 653 |
|
|
|a obesity
|
| 653 |
|
|
|a biomarker
|
| 653 |
|
|
|a BRVO
|
| 653 |
|
|
|a ocular biomarkers
|
| 653 |
|
|
|a OCTA
|
| 653 |
|
|
|a central corneal thickness
|
| 653 |
|
|
|a baseline intraocular pressure
|
| 653 |
|
|
|a outer
|
| 653 |
|
|
|a microperimetry
|
| 653 |
|
|
|a polymorphism
|
| 653 |
|
|
|a fractalkine
|
| 653 |
|
|
|a oxidative stress
|
| 653 |
|
|
|a susceptibility
|
| 653 |
|
|
|a blood flow
|
| 653 |
|
|
|a NTG
|
| 653 |
|
|
|a optical coherence tomography angiography
|
| 653 |
|
|
|a tumbling skills
|
| 653 |
|
|
|a intraocular pressure
|
| 653 |
|
|
|a lamina cribrosa
|
| 653 |
|
|
|a corneal hysteresis
|
| 653 |
|
|
|a ripasudil
|
| 653 |
|
|
|a young adults
|
| 653 |
|
|
|a multifocal visual evoked potentials
|
| 653 |
|
|
|a mfVEP
|
| 653 |
|
|
|a corneal biomechanics
|
| 653 |
|
|
|a Medicine and Nursing / bicssc
|
| 653 |
|
|
|a ocular hypertension
|
| 653 |
|
|
|a ocular inflammation
|
| 653 |
|
|
|a myopia
|
| 653 |
|
|
|a crocin
|
| 653 |
|
|
|a open-angle glaucoma
|
| 700 |
1 |
|
|a Pinazo-Duran, Maria Dolores
|
| 700 |
1 |
|
|a Garcia-Medina, Jose Javier
|
| 700 |
1 |
|
|a Pinazo-Duran, Maria Dolores
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
| 500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by/4.0/
|
| 024 |
8 |
|
|a 10.3390/books978-3-0365-3836-5
|
| 856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/81034
|z DOAB: description of the publication
|
| 856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/5376
|7 0
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a In the past few years, knowledge about glaucoma diagnosis and follow up has evolved dramatically through advances in intraocular pressure (IOP) measurement, corneal biomechanics, structural and functional assessment of the ocular surface, anterior chamber, retina, optic nerve and intracranial visual pathways, as well as the advent of artificial intelligence. In addition, the development of new modalities of IOP-lowering and non-IOP-lowering drugs, alternative deliveries, refined laser technologies, and minimally invasive glaucoma surgery (MIGS) techniques with different implants have widened the therapeutic possibilities for treating this disease. Finally, current insights into risk factors and quality of life in relation to glaucomatous impairment are emerging. The purpose of this Special Issue is to present the latest exciting clinical developments that are taking place in the field of glaucoma.
|